Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
Control of acute, chronic, and constitutive hyperammonemia by wild-type and genetically engineered Lactobacillus plantarum in rodents.
Charles Nicaise,Deborah Prozzi,Eric Viaene,Christophe Moreno,Thierry Gustot,Eric Quertinmont,Pieter Demetter,Valérie Suain,Philippe Goffin,Jacques Devière,Pascal Hols +10 more
TL;DR: Hyperammonemia in constitutive model or after acute or chronic induced liver failure can be controlled by the administration of L. plantarum with a significant effect on survival and the mechanism involved in this ammonia decrease implicates direct ammonia consumption in the gut.
Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen.
Suzanne Bourgeois,Yves Horsmans,Frederik Nevens,Hans Van Vlierberghe,Christophe Moreno,Maria Beumont,Leen Vijgen,Veerle Van Eygen,Donghan Luo,Vera Hillewaert,Pieter Van Remoortere,Jolanda van de Logt,Sivi Ouwerkerk-Mahadevan +12 more
TL;DR: The magnitude of interaction between simeprevir and ledipasvir and the limited amount of safety data available, the use of this treatment combination is not recommended.
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.
Eric Trepo,Andrej Potthoff,Pierre Pradat,Pierre Pradat,Rakesh K. Bakshi,Bradford A. Young,Robert Lagier,Christophe Moreno,Laurine Verset,Richard Cross,Delphine Degré,Arnaud Lemmers,Thierry Gustot,Pascale Berthillon,Pascale Berthillon,William Rosenberg,Christian Trepo,Christian Trepo,John J. Sninsky,Michael Adler,Heiner Wedemeyer +20 more
TL;DR: Although conducted on a limited number of patients, this study in two independent centres confirms that the CRS predicts fibrosis progression in initially mild CHC.
Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance.
Nathalie Ganne-Carrié,Nathalie Ganne-Carrié,Pierre Nahon,Pierre Nahon,Cendrine Chaffaut,Gisèle N'Kontchou,Richard Layese,Etienne Audureau,Sylvie Chevret,Isabelle Archambeaud,Louis d’Alteroche,Frédéric Oberti,Dominique Roulot,Christophe Moreno,Alexandre Louvet,Thong Dao,Romain Moirand,Odile Goria,Eric Nguyen-Khac,Nicolas Carbonell,Jean-Charles Duclos-Vallée,Stanislas Pol,Stanislas Pol,Victor de Ledinghen,Violaine Ozenne,Jean Henrion,Jean-Marie Péron,Albert Tran,Gabriel Perlemuter,Xavier Amiot,Jean-Pierre Zarski,Tarik Asselah,Dominique Guyader,Hélène Fontaine,Georges-Philippe Pageaux,Denis Ouzan,Fabien Zoulim,Jean-Pierre Bronowicki,Thomas Decaens,Ghassan Riachi,Paul Calès,Laurent Alric,Marc Bourlière,Philippe Mathurin,Sébastien Dharancy,Jean-Frédéric Blanc,Armand Abergel,Olivier Chazouillères,Ariane Mallat,Jean-Didier Grangé,Pierre Attali,Claire Wartelle,Dominique Thabut,Christophe Pilette,Christine Silvain,Christos Christidis,Brigitte Bernard-Chabert,Sophie Hillaire,Vincent Di Martino +58 more
- 01 Jun 2021
TL;DR: Compared to patients with virus-related cirrhosis, patients with alcohol-related compensated CirVir enrolled in a surveillance program have a lowest five-year HCC incidence and poorer prognosis, despite similar access to first-line curative treatment.
Combination of Gene Expression Signature and Model for End-stage Liver Disease Score Predicts Survival of Patients With Severe Alcoholic Hepatitis
Eric Trepo,Nicolas Goossens,Nicolas Goossens,Naoto Fujiwara,Won-Min Song,Antonio Colaprico,Astrid Marot,Laurent Spahr,Pieter Demetter,Christine Sempoux,Gene Y. Im,Joan Saldarriaga,Thierry Gustot,Jacques Devière,Swan N. Thung,Charlotte Minsart,Thomas Sersté,Gianluca Bontempi,Karim Abdelrahman,Jean Henrion,Delphine Degré,Valerio Lucidi,Laura Rubbia-Brandt,Venugopalan D. Nair,Christophe Moreno,Pierre Deltenre,Pierre Deltenre,Yujin Hoshida,Denis Franchimont +28 more
TL;DR: The gs-MELD scoring system is developed, which identifies patients with severe AH, treated or not with corticosteroids, most and least likely to survive for 90 and 180 days, which outperformed other clinical models to predict survival.